A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Autor: Khan A; Div. of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Benthin C; Div. of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Zeno B; Riverside Methodist Hospital, Columbus, OH, USA., Albertson TE; School of Medicine, University of California, Davis, Sacramento, CA, USA., Boyd J; St. Paul's Hospital, Vancouver, BC, Canada., Christie JD; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Hall R; Nova Scotia Health Authority and Dalhousie University, Halifax, NS, Canada., Poirier G; Charles LeMoyne Hospital, Sherbrooke University, Greenfield Park, QC, Canada., Ronco JJ; Critical Care Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada., Tidswell M; Division of Pulmonary and Critical Care, Department of Medicine, Baystate Medical Center, Springfield, MA, USA., Hardes K; GlaxoSmithKline R&D, Stockley Park, UK., Powley WM; GlaxoSmithKline R&D, Stevenage, UK., Wright TJ; GlaxoSmithKline R&D, Stevenage, UK., Siederer SK; GlaxoSmithKline R&D, Stevenage, UK., Fairman DA; GlaxoSmithKline R&D, Stevenage, UK., Lipson DA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; GlaxoSmithKline R&D, King of Prussia, PA, USA., Bayliffe AI; GlaxoSmithKline R&D, Stevenage, UK., Lazaar AL; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. aili.l.lazaar@gsk.com.; GlaxoSmithKline R&D, King of Prussia, PA, USA. aili.l.lazaar@gsk.com.

Publikováno v: Critical care (London, England) [Crit Care] 2017 Sep 07; Vol. 21 (1), pp. 234. Date of Electronic Publication: 2017 Sep 07.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Autor: Boscia JA; CU Pharmaceutical Research, Union, South Carolina 29379, USA. joseph@cupharmresearch.com, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C

Publikováno v: Clinical therapeutics [Clin Ther] 2012 Aug; Vol. 34 (8), pp. 1655-66.e5. Date of Electronic Publication: 2012 Jul 11.

A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.

Autor: Miller, Ami¹, Leach, Adam¹, Thomas, Jemima¹, McAndrew, Craig¹, Bentley, Emma², Mattiuzzo, Giada², John, Lijo^3,4, Mirazimi, Ali^3,4, Harris, Gemma⁵, Gamage, Nadisha⁶, Carr, Stephen⁵, Ali, Hanif⁷, Van Montfort, Rob¹, Rabbitts, Terence¹ terry.rabbitts@icr.ac.uk

Publikováno v: Scientific Reports. 5/19/2021, Vol. 11 Issue 1, p1-13. 13p.

Urine concentrations of vilanterol and its metabolites, GSK932009 and GW630200, after inhalation of therapeutic and supratherapeutic doses.

Autor: Østergaard, Martin, Jessen, Søren, Hansen, Erik Søren Halvard, Backer, Vibeke, Panchal, Tina, Baldwin, Sandra, Daley‐Yates, Peter, Hostrup, Morten

Publikováno v: Drug Testing & Analysis; May2023, Vol. 15 Issue 5, p516-528, 13p

The dilemma of renin-angiotensin system inhibitors in coronavirus disease 2019 (COVID-19): insights into lung fluid handling and gas exchange in heart failure patients.

Autor: Guazzi, Marco¹ (AUTHOR) marco.guazzi@unimi.it, Moroni, Alice¹ (AUTHOR)

Publikováno v: European Journal of Heart Failure. Jun2020, Vol. 22 Issue 6, p926-928. 3p. 1 Diagram.